ADVFN ADVFN

Hot Features

Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Swedish Orphan Biovitrum AB (PK)

Swedish Orphan Biovitrum AB (PK) (BIOVF)

48.00
0.00
(0.00%)
終了 6月23日 5:00AM

Swedish Orphan Biovitrum AB (PK) (BIOVF) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

主要統計と詳細

通貨
48.00
( - )
買値
30.50
売値
63.36
出来高
-
0.00 日の範囲 0.00
28.935 52 週間の範囲 48.00
時価総額
前日終値
48.00
始値
-
時刻
最終取引時間
財務取引量
-
VWAP
-
平均取引量 (3 か月)
US$ 432,829
発行済株式数
345,845,189
配当利回り
PER
166.8
1 株当たり利益 (EPS)
2.64
歳入
28.96B
純利益
921M

Swedish Orphan Biovitrum AB (PK) について

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers ... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden. 詳細を表示

セクター
Healthcare
業界
Pharmaceuticals
ウェブサイト
本社
Stockholm, Sweden
設立
2026
Swedish Orphan Biovitrum AB (PK) is listed in the Healthcare sector of the その他OTC with ticker BIOVF. The last closing price for Swedish Orphan Biovitrum... (PK) was US$48. Over the last year, Swedish Orphan Biovitrum... (PK) shares have traded in a share price range of US$ 28.935 to US$ 48.00.

Swedish Orphan Biovitrum... (PK) currently has 345,845,189 shares in issue. The market capitalisation of Swedish Orphan Biovitrum... (PK) is US$16.60 billion. Swedish Orphan Biovitrum... (PK) has a price to earnings ratio (PE ratio) of 166.80.

BIOVF 最新ニュース

表示するニュースはありません。
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10000000CS
40048484810048CS
128.129920.39096967439.87014839.870110045.55335CS
2611.41531.201312013136.5854836.58512641.33406415CS
5218.7564.102564102629.254828.93514534.82485778CS
15628.555146.85008999719.4454818.3548727.19299007CS
26031182.352941176174817101022.85193937CS

BIOVF - Frequently Asked Questions (FAQ)

What is the current Swedish Orphan Biovitrum AB (PK) share price?
The current share price of Swedish Orphan Biovitrum AB (PK) is US$ 48.00
How many Swedish Orphan Biovitrum AB (PK) shares are in issue?
Swedish Orphan Biovitrum AB (PK) has 345,845,189 shares in issue
What is the market cap of Swedish Orphan Biovitrum AB (PK)?
The market capitalisation of Swedish Orphan Biovitrum AB (PK) is USD 16.6B
What is the 1 year trading range for Swedish Orphan Biovitrum AB (PK) share price?
Swedish Orphan Biovitrum AB (PK) has traded in the range of US$ 28.935 to US$ 48.00 during the past year
What is the PE ratio of Swedish Orphan Biovitrum AB (PK)?
The price to earnings ratio of Swedish Orphan Biovitrum AB (PK) is 166.8
What is the cash to sales ratio of Swedish Orphan Biovitrum AB (PK)?
The cash to sales ratio of Swedish Orphan Biovitrum AB (PK) is 5.26
What is the registered address of Swedish Orphan Biovitrum AB (PK)?
The registered address for Swedish Orphan Biovitrum AB (PK) is Norra Stationsgatan 93A, Stockholm, Stockholm County
What is the Swedish Orphan Biovitrum AB (PK) website address?
The website address for Swedish Orphan Biovitrum AB (PK) is www.sobi.com
Which industry sector does Swedish Orphan Biovitrum AB (PK) operate in?
Swedish Orphan Biovitrum AB (PK) operates in the Pharmaceuticals sector

BIOVF 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード

最近閲覧した銘柄

Delayed Upgrade Clock